Oppenheimer Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Oppenheimer Asset Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,087	Closed	-$15K	–	1484
2020 Q1	$15K	Buy	1,087 +155	+17%	+$2.94K	﹤0.01%	1405
2019 Q4	$23K	Sell	932 -429	-32%	-$8.88K	﹤0.01%	1442
2019 Q3	$26K	Buy	1,361 +29	+2%	+$664	﹤0.01%	1434
2019 Q2	$39K	Buy	1,332 +341	+34%	+$13.1K	﹤0.01%	1408
2019 Q1	$47K	Buy	+991	New	+$43.6K	﹤0.01%	1364
2017 Q4	–	Sell	-182	Closed	-$9K	–	1549
2017 Q3	$9K	Sell	182 -6	-3%	-$327	﹤0.01%	1536
2017 Q2	$10K	Sell	188 -12	-6%	-$559	﹤0.01%	1516
2017 Q1	$9K	Buy	+200	New	+$8.92K	﹤0.01%	1544

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Oppenheimer Asset Management's AERI Position: Q2 2020 in Review

Oppenheimer Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2020, closing a stake of 1,087 shares — an estimated $15K sold.

Oppenheimer Asset Management first reported a position in AERI in Q1 2017 and held it in 8 quarters. The position peaked at $47K in Q1 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

Oppenheimer Asset Management reported no remaining Aerie Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Oppenheimer Asset Management sold 1,087 Aerie Pharmaceuticals shares in Q2 2020, an estimated $15K.
Oppenheimer Asset Management first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 8 quarters.
Oppenheimer Asset Management's Aerie Pharmaceuticals position peaked at $47K in Q1 2019.
155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on Oppenheimer Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.